Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 0.62 |
| ▸ | DRD3 | P35462 | 6/20 | 0.62 |
| ▸ | DRD2 | P14416 | 5/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5960057 | 0.89 | PDE4A (0.52) | HTR6DRD3DRD2HRH3GAA | |
| SCHEMBL30015410 | 0.83 | LMNA (0.53) | HTR6DRD3DRD2GAAPDE4A | |
| SCHEMBL13711071 | 0.80 | HTR6 (0.66) | HTR6DRD3DRD2HRH3CYP3A4 | |
| SCHEMBL5960101 | 0.79 | MEN1 (0.61) | HTR6DRD3DRD2GAAPDE4A | |
| SCHEMBL5461753 | 0.78 | PDE4A (0.46) | HTR6GFERPDE4APDE4BPDE4C | |
| SCHEMBL14415236 | 0.77 | HTR6 (0.64) | HTR6DRD3DRD2HRH3SMN1; SMN2 | |
| SCHEMBL14415301 | 0.76 | HTR6 (0.81) | HTR6 | |
| SCHEMBL5960047 | 0.75 | TSHR (0.56) | GAASMN1; SMN2 | |
| SCHEMBL14415499 | 0.75 | HTR6 (0.62) | HTR6DRD3DRD2HRH3 | |
| SCHEMBL5461599 | 0.75 | KMT2A (0.54) | HTR6PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7049468-B2 | Modulators of Rho C activity | ICONIX PHARMACEUTICALS, INC. (US) | 2006-05-23 | — | — | US | disclosed |
| EP-1453470-A4 | MODULATORS OF RHO C ACTIVITY | ICONIX PHARM INC (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1453470-A1 | MODULATORS OF RHO C ACTIVITY | Iconix Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030171341-A1 | Method for modulating the activity of a Rho C enzyme, comprising: contacting said Rho C enzyme with an effective amount of a compound of formula 1: | ENTELOS HOLDING CORP. | 2003-09-11 | — | — | US | disclosed |
| WO-2003043578-A2 | MODULATORS OF RHO C ACTIVITY | ICONIX PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171341-A1 | Method for modulating the activity of a Rho C enzyme, comprising: contacting said Rho C enzyme with an effective amount of a compound of formula 1: | RHOC, RHOA, ROCK1 | HTR6 3458/4885DRD3 2675/4885DRD2 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.